Overview This page contains the latest trade data of Erythromycin, derivatives, in bulk, salts. In 2022, Erythromycin, derivatives, in bulk, salts were the world's 3033rd most traded product, with a total trade of $450M. Between 2021 and 2022 the exports of Erythromycin, derivatives, in bulk, salts grew by 12.1%, from $401M to $450M. Trade in Erythromycin, derivatives, in bulk, salts represent 0.0019% of total world trade.
Erythromycin, derivatives, in bulk, salts are a part of Antibiotics.
Exports In 2022 the top exporters of Erythromycin, derivatives, in bulk, salts were China ($245M), India ($88.1M), United States ($44.2M), Spain ($10M), and Netherlands ($9.44M).
Imports In 2022 the top importers of Erythromycin, derivatives, in bulk, salts were India ($105M), Japan ($32.6M), Croatia ($24.7M), Pakistan ($16.3M), and South Korea ($15.7M).
Ranking Erythromycin, derivatives, in bulk, salts ranks 1995th in the Product Complexity Index (PCI).
Description Erythromycin is primarily used as an antibiotic. It is also used as a drug to treat some bacterial infections and as a drug to prevent traveler's diarrhea. It can block the action of certain enzymes and as a result interfere with the bacteria's ability to make cell walls.